Salivary IgA antibodies to cyclic citrullinated peptides (CCP) in rheumatoid arthritis

Immunobiology

Volumn 218, Issue 2, 2013, Pages 232-237

  Svärd, Anna ^a,b   Kastbom, Alf ^a   Sommarin, Yngve ^c   Skogh, Thomas ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b FALUN HOSPITAL   (Sweden)

^c EuroDiagnostica AB   (Sweden)

Author keywords

Citrullinated peptides; IgA; Mucosal immunity; Rheumatoid arthritis; Saliva

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ADULT; AGED; ANALYTICAL PARAMETERS; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; ARTICLE; BONE EROSION; CONTROLLED STUDY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY CYCLIC ARGININE PEPTIDE ANTIBODY RATIO; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MUCOSAL IMMUNITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SALIVA ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BINDING, COMPETITIVE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN A, SECRETORY; IMMUNOMODULATION; JOINTS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SALIVA;

EID: 84871923115     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.04.011     Document Type: Article

References (51)

1. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., Birnbaum N.S., Burmester G.R., Bykerk V.P., Cohen M.D., et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62:2569.
2. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31:315.
3. Bäcklund J., Nandakumar K.S., Bockermann R., Mori L., Holmdahl R. Genetic control of tolerance to type II collagen and development of arthritis in an autologous collagen-induced arthritis model. J. Immunol. 2003, 171:3493.
4. Baumgarth N. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat. Rev. Immunol. 2011, 11:34.
5. Berglin E., Johansson T., Sundin U., Jidell E., Wadell G., Hallmans G., Rantapää-Dahlqvist S. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann. Rheum. Dis. 2006, 65:453.
6. Brandtzaeg P. Do salivary antibodies reliably reflect both mucosal and systemic immunity?. Ann. N. Y. Acad. Sci. 2007, 1098:288.
7. Brandtzaeg P. Function of mucosa-associated lymphoid tissue in antibody formation. Immunol. Invest. 2010, 39:303.
8. Cerutti A., Chen K., Chorny A. Immunoglobulin responses at the mucosal interface. Annu. Rev. Immunol. 2011, 29:273.
9. Chase M.W. Inhibition of experimental drug allergy by prior feeding of the sensitizing agent. Proc. Soc. Exp. Biol. Med. 1946, 61:257.
10. Chu J.L., Gharavi A.E., Elkon K.B. Spectrotypic analysis of IgM and IgA rheumatoid factors. Clin. Exp. Immunol. 1986, 63:601.
11. Doube A., Collins A.J. Is the gut intrinsically abnormal in rheumatoid arthritis?. Ann. Rheum. Dis. 1988, 47:617.
12. Dunne J.V., Carson D.A., Spiegelberg H.L., Alspaugh M.A., Vaughan J.H. IgA rheumatoid factor in the sera and saliva of patients with rheumatoid arthritis and Sjogren's syndrome. Ann. Rheum. Dis. 1979, 38:161.
13. Ekdahl C., Eberhardt K., Andersson S.I., Svensson B. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand. J. Rheumatol. 1988, 17:263.
14. Elkon K.B., Gharavi A.E., Patel B.M., Hughes G.R.V., Frankel A. IgA and IgM rheumatoid factors in serum, saliva and other secretions: relationship to immunoglobulin ratios in systemic sicca syndrome and rheumatoid arthritis. Clin. Exp. Immunol 1983, 52:75.
15. Forslind K., Ahlmen M., Eberhardt K., Hafström I., Svensson B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann. Rheum. Dis. 2004, 63:1090.
16. Hitchon C.A., Chandad F., Ferucci E.D., Willemze A., Ioan-Facsinay A., van der Woude D., Markland J., Robinson D., Elias B., Newkirk M., et al. Antibodies to Porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives. J. Rheumatol. 2010, 37:1105.
17. Houssien D.A., Jonsson T., Davies E., Scott D.L. Clinical significance of IgA rheumatoid factor subclasses in rheumatoid arthritis. J. Rheumatol. 1997, 24:2119.
18. Huizinga T.W., Amos C.I., van der Helm-van Mil A.H., Chen W., van Gaalen F.A., Jawaheer D., Schreuder G.M., Wener M., Breedveld F.C., Ahmad N., et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 2005, 52:3433.
19. Kastbom A., Strandberg G., Lindroos A., Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann. Rheum. Dis. 2004, 63:1085.
20. Kokkonen H., Mullazehi M., Berglin E., Hallmans G., Wadell G., Rönnelid J., Rantapää-Dahlqvist S. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res. Ther. 2011, 13:R13.
21. Lindqvist E., Eberhardt K., Bendtzen K., Heinegard D., Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann. Rheum. Dis. 2005, 64:196.
22. Lundberg K., Nijenhuis S., Vossenaar E.R., Palmblad K., van Venrooij W.J., Klareskog L., Zendman A.J., Harris H.E. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res. Ther. 2005, 7:R458.
23. Lundberg K., Wegner N., Yucel-Lindberg T., Venables P.J. Periodontitis in RA-the citrullinated enolase connection. Nat. Rev. Rheumatol. 2010, 6:727.
24. McGraw W.T., Potempa J., Farley D., Travis J. Purification, characterization, and sequence analysis of a potential virulence factor from Porphyromonas gingivalis, Peptidylarginine deiminase. Infect. Immun. 1999, 67:3248.
25. Mestecky J., Russell M.W., Elson C.O. Perspectives on mucosal vaccines: is mucosal tolerance a barrier?. J. Immunol. 2007, 179:5633.
26. Mikuls T., Payne J., Reinhardt R., Thiele G., Maziarz E., Cannella A., Holers V., Kuhn K., O'Dell J. Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis. Int. Immunopharmacol. 2009, 9:38.
27. Morgan A.W., Thomson W., Martin S.G., Yorkshire Early Arthritis Register Consortium, Carter A.M., UK Rheumatoid Arthritis Genetics Consortium, Erlich H.A., Barton A., Hocking L., Reid D.M., et al. Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. Arthritis Rheum. 2009, 60:2565.
28. Mullazehi M., Mathsson L., Lampa J., Rönnelid J. High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onset. Ann. Rheum. Dis. 2007, 66:537.
29. Olhagen B., Månsson I. Intestinal clostridium perfringens in rheumatoid arthritis and other collagen diseases. Acta Med. Scand. 1968, 184:395.
30. Otten H.G., Daha M.R., van der Maarl M.G., Hoogendoorn L.I., Beem E.M., de Rooy H.H., Breedveld F.C. IgA rheumatoid factor in mucosal fluids and serum of patients with rheumatoid arthritis: immunological aspects and clinical significance. Clin. Exp. Immunol. 1992, 90:256.
31. Padyukov L., Seielstad M., Ong R.T., Ding B., Rönnelid J., Seddighzadeh M., Alfredsson L., Klareskog L. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann. Rheum. Dis. 2011, 70:259. The Epidemiological Investigation of Rheumatoid Arthritis (EIRA) Study Group.
32. Prevoo M.L., van't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38:44.
33. Raza K., Mullazehi M., Salmon M., Buckley C.D., Rönnelid J. Anti-collagen type II antibodies in patients with very early synovitis. Ann. Rheum. Dis. 2008, 67:1354.
34. Rosenstein E., Greenwald R., Kushner L., Weissmann G. Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis. Inflammation 2004, 28:311.
35. Russell M.W., Ogra P.L. Mucosal decisions: tolerance and responsiveness at mucosal surfaces. Immunol. Invest. 2010, 39:297.
36. Scheinecker C., Smolen J.S. Rheumatoid arthritis in 2010: from the gut to the joint. Nat. Rev. Rheumatol. 2011, 7:73.
37. Skogh T. Overestimate of 125I-protein uptake from the adult mouse gut. Gut 1982, 23:1077.
38. Skogh T., Edebo L., Stendahl O. Gastrointestinal uptake and blood clearance of antigen in the presence of IgA antibodies. Immunology 1983, 50:175.
39. Stokes C.R., Soothill J.F., Turner M.W. Immune exclusion is a function of IgA. Nature 1975, 255:745.
40. Suzuki K., Maruya M., Kawamoto S., Fagarasan S. Roles of B-1 and B-2 cells in innate and acquired IgA-mediated immunity. Immunol. Rev. 2010, 237:180.
41. Svärd A., Kastbom A., Reckner-Olsson A., Skogh T. Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project. Arthritis Res. Ther. 2008, 10:R75.
42. Svärd A., Kastbom A., Söderlin M.K., Reckner-Olsson A., Skogh T. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis. J. Rheumatol. 2010, 38:1265.
43. Toussirot E.A. Oral tolerance in the treatment of rheumatoid arthritis. Curr. Drug Targets Inflamm. Allergy 2002, 1:45.
44. Trentham D.E., Dynesius-Trentham R.A., Orav E.J., Combitchi D., Lorenzo C., Sewell K.L., Hafler D.A., Weiner H.L. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993, 261:1727.
45. Trollmo C., Sollerman C., Carlsten H., Tarkowski A. The gut as an inductive site for synovial and extra-articular immune responses in rheumatoid arthritis. Ann. Rheum. Dis. 1994, 53:377.
46. Uysal H., Bockermann R., Nandakumar K.S., Sehnert B., Bajtner E., Engström å., Serre G., Burkhardt H., Thunnissen M.M.G.M., Holmdahl R. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J. Exp. Med. 2009, 206:449.
47. van der Woude D., Rantapää-Dahlqvist S., Ioan-Facsinay A., Onnekink C., Schwarte C.M., Verpoort K.N., Drijfhout J.W., Huizinga T.W., Toes R.E., Pruijn G.J. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann. Rheum. Dis. 2010, 69:1554.
48. van Gaalen F.A., Linn-Rasker S.P., van Venrooij W.J., de Jong B.A., Breedveld F.C., Verweij C.L., Toes R.E., Huizinga T.W. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis, a prospective cohort study. Arthritis Rheum. 2004, 50:709.
49. Weiner H.L., da Cunha A.P., Quintana F., Wu H. Oral tolerance. Immunol. Rev. 2011, 241:241.
50. Verpoort K.N., Jol-van der Zijde C.M., Papendrecht-van der Voort E.A., Ioan-Facsinay A., Drijfhout J.W., van Tol M.J., Breedveld F.C., Huizinga T.W., Toes R.E. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum. 2006, 54:3799.
51. Verpoort K.N., Papendrecht-van der Voort E.A., van der Helm-van Mil A.H., Jol-van der Zijde C.M., van Tol M.J., Drijfhout J.W., Breedveld F.C., de Vries R.R., Huizinga T.W., Toes R.E. Association of smoking with the constitution of the anti-cyclic citrullinated peptide response in the absence of HLA-DRB1 shared epitope alleles. Arthritis Rheum. 2007, 56:2913.